JP2017537973A5 - - Google Patents

Info

Publication number

JP2017537973A5

JP2017537973A5 JP2017540317A JP2017540317A JP2017537973A5 JP 2017537973 A5 JP2017537973 A5 JP 2017537973A5 JP 2017540317 A JP2017540317 A JP 2017540317A JP 2017540317 A JP2017540317 A JP 2017540317A JP 2017537973 A5 JP2017537973 A5 JP 2017537973A5

Authority

JP

Japan

Prior art keywords

patient

level

composition

item

day

Prior art date

2015-10-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 198
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 119
• 108091034117 Oligonucleotide Proteins 0.000 claims description 87
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 84
• 238000012230 antisense oligonucleotides Methods 0.000 claims description 84
• 102000004890 Interleukin-8 Human genes 0.000 claims description 76
• 108090001007 Interleukin-8 Proteins 0.000 claims description 76
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 76
• 229940096397 interleukin-8 Drugs 0.000 claims description 76
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 74
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 74
• 101700026522 SMAD7 Proteins 0.000 claims description 72
• 102000049873 Smad7 Human genes 0.000 claims description 72
• 125000003729 nucleotide group Chemical group 0.000 claims description 22
• 239000002773 nucleotide Substances 0.000 claims description 21
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 20
• 208000011231 Crohn disease Diseases 0.000 claims description 18
• LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 claims description 9
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
• 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 4
• 210000004369 blood Anatomy 0.000 claims description 4
• 239000008280 blood Substances 0.000 claims description 4
• 230000009266 disease activity Effects 0.000 claims description 4
• 210000002381 plasma Anatomy 0.000 claims description 4
• 210000002966 serum Anatomy 0.000 claims description 4
• 102000019034 Chemokines Human genes 0.000 claims description 2
• 108010012236 Chemokines Proteins 0.000 claims description 2
• 239000003446 ligand Substances 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 55
• 102100040247 Tumor necrosis factor Human genes 0.000 claims 3
• 108010074051 C-Reactive Protein Proteins 0.000 description 9
• 102100032752 C-reactive protein Human genes 0.000 description 9
• 238000002965 ELISA Methods 0.000 description 6
• 101000652166 Homo sapiens Mothers against decapentaplegic homolog 7 Proteins 0.000 description 6
• 102000044356 human SMAD7 Human genes 0.000 description 6
• 238000007726 management method Methods 0.000 description 6
• 231100000682 maximum tolerated dose Toxicity 0.000 description 6
• 150000003431 steroids Chemical class 0.000 description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 235000006694 eating habits Nutrition 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 230000000391 smoking effect Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 2
• ABASMUXUCSQFKC-PKEKLUKKSA-N mongersen Chemical compound CC1=CN([C@H]2C[C@H](OP(=S)(O)OC[C@H]3O[C@H](C[C@@H]3OP(=S)(O)OC[C@H]4O[C@H](C[C@@H]4OP(=S)(O)OC[C@H]5O[C@H](C[C@@H]5OP(=S)(O)OC[C@H]6O[C@H](C[C@@H]6OP(=S)(O)OC[C@H]7O[C@H](C[C@@H]7O)N8C=CC(=NC8=O)N)n9cnc%10C(=O)NC(=Nc9%10)N)n%11cnc%12c(N)ncnc%11%12)N%13C=CC(=NC%13=O)N)n%14cnc%15C(=O)NC(=Nc%14%15)N)[C@@H](COP(=S)(O)O[C@H]%16C[C@@H](O[C@@H]%16COP(=S)(O)O[C@H]%17C[C@@H](O[C@@H]%17COP(=S)(O)O[C@H]%18C[C@@H](O[C@@H]%18COP(=S)(O)O[C@H]%19C[C@@H](O[C@@H]%19COP(=S)(O)O[C@H]%20C[C@@H](O[C@@H]%20COP(=S)(O)O[C@H]%21C[C@@H](O[C@@H]%21COP(=S)(O)O[C@H]%22C[C@@H](O[C@@H]%22COP(=S)(O)O[C@H]%23C[C@@H](O[C@@H]%23COP(=S)(O)O[C@H]%24C[C@@H](O[C@@H]%24COP(=S)(O)O[C@H]%25C[C@@H](O[C@@H]%25COP(=S)(O)O[C@H]%26C[C@@H](O[C@@H]%26COP(=S)(O)O[C@H]%27C[C@@H](O[C@@H]%27COP(=S)(O)O[C@H]%28C[C@@H](O[C@@H]%28COP(=S)(O)O[C@H]%29C[C@@H](O[C@@H]%29COP(=S)(O)O[C@H]%30C[C@@H](O[C@@H]%30CO)n%31cnc%32C(=O)NC(=Nc%31%32)N)N%33C=C(C)C(=O)NC%33=O)N%34C=C(C)C(=NC%34=O)N)n%35cnc%36C(=O)NC(=Nc%35%36)N)N%37C=CC(=NC%37=O)N)N%38C=CC(=NC%38=O)N)N%39C=CC(=NC%39=O)N)N%40C=CC(=NC%40=O)N)N%41C=C(C)C(=O)NC%41=O)N%42C=C(C)C(=O)NC%42=O)N%43C=CC(=NC%43=O)N)N%44C=C(C)C(=O)NC%44=O)N%45C=CC(=NC%45=O)N)N%46C=CC(=NC%46=O)N)N%47C=CC(=NC%47=O)N)O2)C(=O)N=C1N ABASMUXUCSQFKC-PKEKLUKKSA-N 0.000 description 1
• 229950002917 mongersen Drugs 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1